Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Regeneron Pharmaceuticals reported fourth-quarter ... fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks ...

And it might even get worse for Regeneron since Amgen's Pavblu, a biosimilar version of Eylea, hit the market only six months ago. In the fourth quarter, combined U.S. sales of Eylea and Eylea HD ...

Regeneron capped 2024 with strong revenue growth and significant strategic moves, including a new dividend and expanded share repurchase program. EYLEA HD remains a key focus, with management ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...